L. Samuel

发表

Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival

P. Murchie, A. Lee, N. Campbell, 2014, British Journal of Cancer.

Effect of longer health service provider delays on stage at diagnosis and mortality in symptomatic breast cancer.

P. Murchie, A. Lee, N. Campbell, 2015, Breast.

Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival

M. Salto‐Tellez, D. McArt, P. Dunne, 2017, Modern Pathology.

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, C. Hardy, U. McDermott, 2020, Gut.

Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.

B. Haylock, C. Topham, L. Samuel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)

R. Swindell, B. Haylock, C. Topham, 2009, British Journal of Cancer.

Hypoxia PET/CT and Colorectal Cancer: A Case Report

K. Kerr, G. Murray, M. Zanda, 2020 .

Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)

M. Convertino, T. Church, A. Barnett, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Predictors of anxiety and depression in people with colorectal cancer

M. Johnston, Amanda J Lee, S. Hall, 2014, Supportive Care in Cancer.

Modifiable and fixed factors predicting quality of life in people with colorectal cancer

S. Wyke, M. Johnston, A. Lee, 2011, British Journal of Cancer.

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.

C. Twelves, L. Samuel, S. Gollins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival

G. Murray, J. Shim, G. Ramsay, 2021, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

T. Kolevska, P. Philip, H. Lenz, 2017, Cancer Chemotherapy and Pharmacology.

A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy

J. Graham, T. Evans, L. Samuel, 2009, Cancer Chemotherapy and Pharmacology.

FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA

R. Butler, P. Quirke, H. Wasan, 2017 .

A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.

M. Nicolson, R. Petty, L. Samuel, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.

E. Levine, R. Glynne-Jones, S. Wan, 2008, International journal of radiation oncology, biology, physics.

Edinburgh Research Explorer Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, U. McDermott, Chieh-Hsi Wu, 2020 .

Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).

R. Glynne-Jones, T. Maughan, D. Sebag‐Montefiore, 2005 .

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

D. Bisset, D. Jodrell, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

M. Nicolson, F. Ahmed, L. Samuel, 2002, British Journal of Cancer.

The expression and prognostic significance of bcl‐2‐associated transcription factor 1 in rectal cancer following neoadjuvant therapy

Graeme I Murray, G. Murray, L. Samuel, 2016, Histopathology.

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, C. Hardy, U. McDermott, 2020, Gut.

Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Jens Rittscher, Clare Verrill, Susan Richman, 2019, bioRxiv.

Title: Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Tomlinson, K. Sirinukunwattana, C. Hardy, 2019 .

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer

R. Butler, J. Graham, P. Quirke, 2022, Clinical trials.

Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy

P. Johnston, D. Longley, L. Messerini, 2018, JCO precision oncology.

Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial.

Leslie Samuel, Gillian Raab, G. Raab, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

P. Quirke, J. Worlding, S. Beare, 2017, British Journal of Cancer.

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer.

N. Douglas, C. Espie, J. Cassidy, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/ II Feasibility Study of Intravenous Cetuximab in Combination with 5 days Weekly Oral Capecitabine and Preoperative Radiotherapy in Rectal Cancer (XERXES)

R. Glynne-Jones, A. Lopes, D. Sebag‐Montefiore, 2019, Archives of Clinical and Biomedical Research.

Tumour-and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial †

J. Ledermann, R. James, D. Cunningham, 2014 .

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Developing a community-based intervention to improve quality of life in people with colorectal cancer: a complex intervention development study

S. Wyke, M. Johnston, Amanda J Lee, 2013, BMJ Open.

Prognostic value of lymph node ratio and extramural vascular invasion on survival for patients undergoing curative colon cancer resection

G. Murray, G. Ramsay, M. Loudon, 2015, British Journal of Cancer.

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

J. Graham, D. Gaya, J. Edwards, 2021, Radiation Oncology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?

G. Murray, G. Ramsay, L. Samuel, 2018, Digestive Surgery.

Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database

C. Cardwell, P. Murchie, C. Hughes, 2021, British Journal of Cancer.

Toward shared care for people with cancer: developing the model with patients and GPs.

Peter Murchie, P. Murchie, S. Hall, 2011, Family practice.

Young-onset colorectal cancer in the North East of Scotland: survival, clinico-pathological features and genetics

Z. Miedzybrodzka, L. Samuel, K. Laws, 2019, BMC Cancer.

A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer.

D. Bissett, C. Wolf, A. Barnett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

H. Hurwitz, J. Bendell, K. Lechner, 2019, The oncologist.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

M. Hidalgo, J. Tabernero, V. Ganju, 2018, Clinical Cancer Research.

APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

E. Aly, G. Murray, S. Semple, 2009, BMC Cancer.

Increased Lymph Node Yield in Colorectal Cancer Is Not Necessarily Associated with a Greater Number of Lymph Node Positive Cancers

G. Murray, M. Loudon, L. Samuel, 2014, PloS one.

ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC).

P. Quirke, S. Bach, R. Glynne-Jones, 2020 .

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Cristina Santos, H. Hurwitz, J. Bendell, 2017 .

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2017, The lancet. Gastroenterology & hepatology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF , PIK3CA , KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R. Butler, S. Richman, L. Samuel, 2018 .

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.

J. Ledermann, R. James, R. Glynne-Jones, 2014, Annals of Oncology.

Cognitive and attentional changes following cognitive behaviour therapy (CBT) for persistent insomnia associated with cancer: a randomized controlled trial

C. Espie, J. Cassidy, L. Fleming, 2008 .

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.

J. Ledermann, R. James, R. Glynne-Jones, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

J. Ledermann, R. James, D. Cunningham, 2013 .

Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

M. Hidalgo, J. Tabernero, V. Ganju, 2015 .

The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).

J. Tabernero, J. Bridgewater, B. Markman, 2012 .